NeuroOne Medical Technologies Corporation
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $171.2K | $178.1K | $0 | $0 | $773 |
| Cost of Revenue | $4.0M | $2.4M | $1.5M | $242.0K | $275.9K | — | — | — |
| Gross Profit | $5.1M | $1.1M | $456.5K | $-70.8K | $-97.7K | — | — | — |
| Gross Margin | 56.5% | 31.3% | 23.4% | -41.4% | -54.9% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.0M | $5.1M | $6.9M | $4.9M | $3.9M | — | — | — |
| SG&A Expense | $7.4M | $7.9M | $6.9M | $7.0M | $6.3M | $32.6K | $30.9K | $36.7K |
| Operating Income | $-4.2M | $-11.9M | $-12.0M | $-10.0M | $-10.2M | $-32.6K | $-30.9K | $-35.9K |
| Operating Margin | -46.5% | -344.3% | -612.3% | -5,860.2% | -5,735.9% | — | — | -4,646.1% |
| Interest Expense | — | — | — | — | $3.1K | — | $14.0K | $330 |
| Pretax Income | $-3.6M | $-12.3M | $-11.9M | $-10.0M | — | $-32.6K | $-30.9K | $-36.2K |
| Income Tax Expense | — | — | — | — | $-271.1K | $0 | $0 | $0 |
| Net Income | $-3.6M | $-12.3M | $-11.9M | $-10.0M | $-9.9M | $-47.8K | $-62.9K | $-36.2K |
| Net Margin | -39.6% | -356.7% | -607.4% | -5,842.0% | -5,584.3% | — | — | -4,688.7% |
| EPS (Basic) | $-0.09 | $-0.46 | $-0.65 | $-0.63 | $-0.93 | $-0.01 | $-0.01 | $-0.01 |
| EPS (Diluted) | $-0.09 | $-0.46 | $-0.65 | $-0.63 | $-0.93 | $-0.01 | $-0.01 | $-0.01 |
| Shares Outstanding (Basic) | 40.2M | 26.8M | 18.1M | 16.0M | 10.7M | 5.2M | 5.1M | 5.1M |
| Shares Outstanding (Diluted) | 40.2M | 26.8M | 18.1M | 16.0M | 10.7M | 5.2M | 5.1M | 5.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |